Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US9382304B2 · kind B2 · utility
3Cited by
3References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 3, 2012 |
| Grant date | Jul 5, 2016 |
| Priority date | — |
| Expiry date | Jul 3, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.